Newsroom

Media

Newsroom - 2024

Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL

16 DEC 2024 | READ MORE

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001 in relapsed/refractory Multiple Myeloma (r/rMM) at ASH Annual Meeting

10 DEC 2024 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

27 NOV 2024 | READ MORE

Glenmark Pharma reports consolidated revenue growth of 7.1% and EBITDA growth of 30.2% YoY for Q2 FY 2024-25

14 NOV 2024 | READ MORE

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting

05 NOV 2024 | READ MORE

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)

19 AUG 2024 | READ MORE

Glenmark Pharma reports consolidated revenue growth of 6.9%, EBITDA margin of 18.1%, and PAT margin of 10.5% YoY for Q1 FY 2024-25

14 AUG 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg

17 JULY 2024 | READ MORE

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

12 JUNE 2024 | READ MORE

Glenmark Pharma Reports Q4 FY2023-24 Financial results

24 MAY 2024 | READ MORE

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

21 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

17 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

29 APRIL 2024 | READ MORE

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

14 FEB 2024 | READ MORE

Glenmark partners with Pfizer to launch Abrocitinib in India

31 JAN 2024 | READ MORE

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’

30 JAN 2024 | READ MORE

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

25 JAN 2024 | READ MORE

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

03 JAN 2024 | READ MORE